Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term chemotherapy. Found 241 abstracts

no pagination
Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G, Nccn Gastric Canc Panel Members. Gastric Cancer Clinical Practice Guidelines in Oncology (TM). Journal of the National Comprehensive Cancer Network. 2010 Apr;8(4):378-409.   PMCID: not NIH funded
Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. Cancer-Related Fatigue. Journal of the National Comprehensive Cancer Network. 2010 Aug;8(8):904-31.   PMCID: not NIH funded
Biermann JS, Adkins DR, Benjamin RS, Brigman B, Chow W, Conrad EU, Frassica DA, Frassica FJ, George S, Hande KR, Hornicek FJ, Letson GD, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, Somaiah N, Yasko AW. Bone Cancer. Journal of the National Comprehensive Cancer Network. 2010 Jun;8(6):688-712.   PMCID: not NIH funded
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu JM, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncology. 2010 Jan;11(1):21-8.   PMCID: not NIH funded
Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J. Soft Tissue Sarcoma. Journal of the National Comprehensive Cancer Network. 2010 Jun;8(6):630-74.   PMCID: not NIH funded
Deng S, Yang XJ, Lassus H, Liang S, Kaur S, Ye QR, Li CS, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang YC, Montone K, Butzow R, Coukos G, Zhang L. Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers. Plos One. 2010 Apr;5(4):E10277.   PMCID: PMCID: PMC2858084
Gopal RS, Dubey S, Rosenzweig KE, Chang JY, Decker R, Gewanter RM, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR APPROPRIATENESS CRITERIA (R) ON INDUCTION AND ADJUVANT THERAPY FOR STAGE N2 NON-SMALL-CELL LUNG CANCER: EXPERT PANEL ON RADIATION ONCOLOGY-LUNG. International Journal of Radiation Oncology Biology Physics. 2010 Nov;78(4):969-74.   PMCID: not NIH funded
Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR, Martin L, Morgan MA, Morgan RJ, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Valea FA. Cervical Cancer. Journal of the National Comprehensive Cancer Network. 2010 Dec;8(12):1388-416.   PMCID: not NIH funded
Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research. 2010 Apr;16(8):2450-7.   PMCID: not NIH funded
Hoffman JP. Status of Neoadjuvant Therapy for Resectable Pancreatic Cancer. Surgical Oncology Clinics of North America. 2010 Apr;19(2):411-+.   PMCID: not NIH funded
Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nature Reviews Clinical Oncology. 2010 Dec;7(12):693-701.
Movsas B, Langer CJ, Ross HJ, Wang LH, Jotte RM, Feigenberg S, Xu F, Huang CH, Monberg MJ, Obasaju CK. Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2010 May;5(5):673-9.   PMCID: not NIH funded
Rose PG, Tian CQ, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2010 May;117(2):324-9.   PMCID: NIH funded - needs PMCID
Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen CH. INITIAL RESULTS OF A PHASE I DOSE-ESCALATION TRIAL OF CONCURRENT AND MAINTENANCE ERLOTINIB AND REIRRADIATION FOR RECURRENT AND NEW PRIMARY HEAD-AND-NECK CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Nov;78(4):1020-5.   PMCID: not NIH funded
Wong YN, Hamilton O, Egleston B, Salador K, Murphy C, Meropol NJ. Understanding How Out-of-Pocket Expenses, Treatment Value, and Patient Characteristics Influence Treatment Choices. The oncologist. 2010 Jan;15(6):566-76.   PMCID: PMCID: PMC2892556 [Available on 2011/1/1]
Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals of Oncology. 2009 Jul;20(7):1242-8.   PMCID: PMC2699385
Earle CC, Weiser MR, Ter Veer A, Skibber JM, Wilson J, Rajput A, Wong YN, Benson AB, Shibata S, Romanus D, Niland J, Schrag D. Effect of Lymph Node Retrieval Rates on the Utilization of Adjuvant Chemotherapy in Stage II Colon Cancer. Journal of surgical oncology. 2009 Dec;100(7):525-8.   PMCID: not NIH funded
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. Colon Cancer. Journal of the National Comprehensive Cancer Network. 2009 Sep;7(8):778-831.   PMCID: no NIH - Practice Guideline
Gold HT, Hall MJ, Blinder V, Schackman BR. Cost Effectiveness of Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Before Irinotecan Administration for Metastatic Colorectal Cancer. Cancer. 2009 Sep;115(17):3858-67.   PMCID: PMC2853177
Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK. Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel and Cisplatin With Radiation Therapy for Patients With Resected High-Risk Head and Neck Squamous Cell Carcinoma: Report of the Phase II Trial RTOG 0024. Journal of Clinical Oncology. 2009 Oct;27(28):4727-32.   PMCID: PMC2754914
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term chemotherapy

chemotherapy surgery NCCN Clinical Practice Guidelines radiation therapy phase-ii trial radiotherapy positron-emission-tomography NCCN Guidelines randomized-trial carcinoma paclitaxel fluorouracil therapy radiation-therapy survival breast-cancer cisplatin chemoradiation 5-fluorouracil oxaliplatin mutations sarcoma irinotecan squamous-cell carcinoma colorectal-cancer docetaxel high-dose oncology group rtog adenocarcinoma Response randomized controlled-trial hodgkins-disease survivors malignant gastroduodenal obstruction patients pts neoplasm recurrence soft tissue laparoscopic in-vivo Docetaxel fatigue colonic neoplasms adjuvant chemotherapy Disease control eortc bone marrow transplantation locally advanced head long-term survival progression phase-iii ewings-sarcoma family controlled-trial randomized trial multicenter phase-ii accelerated fractionation PLUS CISPLATIN 13 european countries placebo-controlled trial combination ADVANCED SOLID TUMORS fluorouracil plus leucovorin growth stage-iii soft tissue extremity sarcoma factor receptor esophageal cancer folinic acid lymph-node micrometastases Gemcitabine tumorigenesis neoadjuvant chemotherapy of-the-literature cancer care postoperative plus cetuximab fluorouracil failure oncology pegylated liposomal colon cancer Progression-free progenitor cells preoperative chemoradiation rectal-cancer l-carnitine supplementation curative resection phase-iii trial treatment ovarian-cancer s-1 plus topotecan cost gastroesophageal carboplatin DNA TOPOISOMERASE-I long-term outcomes primitive neuroectodermal tumors concurrent pathway phenotypic characterization oxaliplatin-based association Stage IIIA gastrointestinal stromal tumors ADJUVANT CHEMOTHERAPY junction adenocarcinoma chondrosarcomas primary extremity sarcoma Neoadjuvant therapy LN retrieval epidermal-growth-factor radical hysterectomy RANDOMIZED-TRIAL ugt1a1-asterisk-28 genotype high-grade osteosarcoma 2-STAGE DESIGNS uterine cervix NSCLC nsclc identification Reirradiation upper gastrointestinal transplantation quality-of-life circulating tumor-cells bone cancer stem-cell rescue platinum-refractory ovarian stem-cell cell lung-cancer Resectable pancreatic adenocarcinoma lymph-node dissection squamous-cell-carcinoma metaanalysis hysterectomy erlotinib screening cell-lung-cancer willingness-to-pay european-osteosarcoma-intergroup B blockade resection (JNCCN desmoid tumor 8:378-409) peritoneal carcinoma doxorubicin of-function Ewing's sarcoma growth-factor receptor folfiri
Last updated on Sunday, July 12, 2020